Recursion Pharmaceuticals: $2.5B valuation, IPO Readiness 57, Public. AI-powered biotech combining biology, chemistry, and machine learning for drug discovery. Track live on The IPO Stack.
AI-powered biotech combining biology, chemistry, and machine learning for drug discovery.
Scores, valuations, and IPO signals for the companies that matter. 5-minute read, every Tuesday.
Top companies most likely to IPO in 2026, ranked by IPO Readiness Score.
Track Recursion Pharmaceuticals IPO timeline, funding rounds, investor activity, and valuation on TechStackIPO — the pre-IPO intelligence platform.
Recursion Pharmaceuticals is already a public company.
Recursion Pharmaceuticals is valued at $2.5B as of April 2021. This valuation is based on its most recent private funding round tracked by TechStackIPO.
Recursion Pharmaceuticals is already a public company. You can invest by purchasing shares on public stock exchanges.
Recursion Pharmaceuticals scores 57/100 (Grade: C) on TechStackIPO's IPO Readiness Index. The score evaluates funding scale, valuation trajectory, funding momentum, stage progression, and company maturity. Scores above 70 indicate strong near-term IPO potential.
Recursion Pharmaceuticals has raised $939M in total venture capital and private equity funding, with backing from Lux Capital, a16z Bio, Baillie Gifford.
Recursion Pharmaceuticals's notable investors include Lux Capital, a16z Bio, Baillie Gifford, Public Markets. Full investor details, funding round history, and lead investor breakdowns are available on TechStackIPO.
Recursion Pharmaceuticals is a Biotechnology company. AI-powered biotech combining biology, chemistry, and machine learning for drug discovery.